


FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 10277/7007(HCL)	SERIAL NO.: 09/470,494
	APPLICANT: Newell et al.	
	FILING DATE: December 22, 1999	GROUP: 1643 1644



U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
PG		5,593,972	01/14/97	Weiner et al.	514	44	
		5,639,939	06/17/97	McCune, III	800	2	
		5,674,492	10/07/97	Armitage et al.	424	144.1	
		5,677,139	10/14/97	Johnson et al.	435	29	
		5,677,165	10/14/97	deBoer et al.	435	240.27	

FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
	WO95/09653	04/13/95	Immunex Corporation	A61K	39/395	
	WO95/10540	04/20/95	Immunex Corporation	C07K	16/28	
	WO97/31025	08/28/97	Chiron Corporation	C07K	16/28	
	WO98/03670	01/29/98	Pangenetics B.V.	C12N	15/86	

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

		Choe, Jongseon et al., Cellular and Molecular Factors That Regulate the Differentiation and Apoptosis of Germinal Center B Cells, <i>Journal of Immunology</i> , 1996, pages 1006-1016
		Fanslow, W.C. et al., Recombinant CD40 Ligand Exerts Potent Biologic Effects on T Cells, <i>Journal of Immunology</i> , 1994, pages 4262-4269
		Foy, T. M. et al., An Essential Role for gp39, the Ligand for CD40, in Thymic Selection, <i>J. Exp. Med.</i> , Vol. 182, November 1995, pages 1377-1388
PL		Schattner, E. J. et al., CD40 Ligation Induces Apo-1/Fas Expression on Human B Lymphocytes and Facilitates Apoptosis through the Apo-1/Fas Pathway, <i>J. Exp. Med.</i> , Vol. 181, 1995, pages 1557-1565

EXAMINER Philip Gamba 3/2/04	DATE CONSIDERED
---------------------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant

JUL 21 2003

FORM PTO/A-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/470,494

ATTY. DOCKET NO.: V00139.70063.US

FILING DATE: December 22, 1999

CONFIRMATION NO.: 6216

APPLICANT: Martha Karen Newell et al.

GROUP ART UNIT: 1644

EXAMINER: Phillip Gambel

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PC	C7	WARE, CARL F. et al., Tumor Necrosis Factor (TNF) Receptor Expression in T Lymphocytes, <i>J. of Immunology</i> 147:4229 (1991).	
PC	C8	WAGNER, DAVID H. JR., Increased Expression of CD40 on Thymocytes and peripheral T cells in autoimmunity: A Mechanism for Acquiring Changes in the Peripheral T Cell Receptor Repertoire, <i>Intl J. of Molecular Medicine</i> 4:231 (1999).	
PC	C9	VAN KOOTEN, CEES, CD40-CD40 Ligand: A Multifunctional Receptor-Ligand Pair, <i>Advances in Immunology</i> , v. 61, p. 1 (1996)	

EXAMINER


Phillip Gambel 3/2/04

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: 10277/7007	SERIAL NO.: 09/470,494
	APPLICANT: Martha K. Newell, et al.	
	FILING DATE: December 22, 1999	GROUP: 1643 1644

U.S. PATENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
MC	A1	5,639,939	6/97	McCune, III	800	2	_____
	A2	5,593,972	1/97	Weiner, et al.	514	44	_____
	A3	5,677,165	10/97	de Boer, et al.	435	240.2	_____
	A4	5,677,139	10/97	Johnson, et al.	435	29	_____
MC	A5	5,674,492	10/97	Armitage, et al.	424	144.1	_____

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	No
MC	B1	WO 98/03670	1/98	PCT				
	B2	WO 97/31025	8/97	PCT				
	B3	WO 95/09653	4/95	PCT				
MC	B4	WO 95/10540	4/95	PCT				

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

MC	C1		Copy of the International Search Report mailed April 26, 2000
	C2		Lipsky, et al., "Analysis of CD40-CD40 Ligand Interactions in the Regulation of Human B Cell Function" <i>Ann. NY. Acad. Sci.</i> , pgs 372-383 (1997).
	C3		Schattner, et al., "CD40 Ligation Induces Apo-1/Fas Expression on Human B Lymphocytes and Facilitates Apoptosis through the Apo-1/Fas Pathway" <i>J Exp Med.</i> 1995 Nov 1;182(5):1557-65
	C4		Fanslow, et al., "Recombinant CD40 Ligand Exerts Potent Biologic Effects on T Cells", <i>J Immunol.</i> 1994 May 1;152(9):4262-9.
	C5		Choe, et al., "Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis", <i>J Immunol.</i> 1996 Aug 1;157(3):1006-16.
MC	C6		Foy, et al., "An Essential Role for gp39, the Ligand for CD40, in Thymic Selection", <i>J. Exp. Med.</i> , 182:1377-1388 (1995)
Examiner: PHILIP G. MAGEE 3/4/04			Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant